BawejaR, FaraoneSV, ChildressAC, et al.From consensus statement to pills to pixels: New innovations in attention-deficit/hyperactivity disorder care. J Child Adolesc Psychopharmacol, 2024; 34(4):167–182; doi: 10.1089/cap.2024.0022
2.
BushnellGA, HortonDB, OlfsonM, et al.Current utilization of bupropion treatment in children, young adults, and adults in the United States. J Child Adolesc Psychopharmacol, 2025; 35(3):135–144; doi: 10.1089/cap.2024.0111
3.
ChildressA, AsubontengK, CoxG, et al.Viloxazine extended-release administered with psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder: A phase 4, open-label trial. J Child Adolesc Psychopharmacol, 2025; 35(3):155–166; doi: 10.1089/cap.2024.0138
4.
IshimuroHS, Yanes-LukinPK, GoldbergPH, et al.Ketamine treatment for pediatric refractory obsessive: Five open-label cases. J Child Adolesc Psychopharmacol, 2025; 35(3):167–170; doi: 10.1089/cap.2024.0127
5.
JacobsE, Insua-SummerhaysB. The psychosocial environment as therapeutic context: Family-centered approaches to adolescent psychedelic research. J Child Adolesc Psychopharmacol, 2025; 35(3):171–172; doi: 10.1089/cap.2025.0007
6.
JeffreyJK, WeintraubMJ, GrobCS. J Clinical Research Trials of Psychedelic-Assisted therapy in adolescents aged 16 to 17 years: Rationale balanced with caution. J Am Acad Child Adolesc Psychiatry, 2024; 63(12):1196–1198; doi: 10.1016/j.jaac.2024.03.021
7.
KohlerK, RosenN, PiacentiniJ. Description, implementation, and efficacy of the comprehensive behavioral intervention for tics as first-line treatment for tourette and other tic disorders. J Child Adolesc Psychopharmacol, 2025; 35(3):126–134; doi: 10.1089/cap.2024.0023
8.
LinehamA, Avila-QuinteroVJ, BlochMH, et al.Exploring predictors of ketamine response in adolescent treatment-resistant depression. J Child Adolesc Psychopharmacol, 2024; 34(2):73–79; doi: 10.1089/cap.2023.0047
9.
StrawnJR, MillsJA, NeptuneZA, et al.Electronically monitored antidepressant adherence in adolescents with anxiety disorders: A pilot study. J Child Adolesc Psychopharmacol, 2025; 35(3):145–154; doi: 10.1089/cap.2024.0102
